Neuren Pharmaceuticals Ltd (NEU)

Currency in AUD
20.800
+0.320(+1.56%)
Closed·
NEU Scorecard
Full Analysis
Management has been aggressively buying back shares
Trading near 52-week High
NEU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.14020.825
52 wk Range
8.61020.825
Key Statistics
Bid/Ask
21.84 / 19.55
Prev. Close
20.8
Open
20.48
Day's Range
20.14-20.825
52 wk Range
8.61-20.825
Volume
634.08K
Average Volume (3m)
542.03K
1-Year Change
50.88%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.513
Upside
+17.85%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Neuren Pharmaceuticals Ltd Company Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.

Employees
8
Market
Australia

Compare NEU to Peers and Sector

Metrics to compare
NEU
Peers
Sector
Relationship
P/E Ratio
17.6x−4.6x−0.6x
PEG Ratio
0.620.000.00
Price/Book
8.1x2.3x2.6x
Price / LTM Sales
12.0x13.0x3.3x
Upside (Analyst Target)
10.6%245.1%38.0%
Fair Value Upside
Unlock3.1%4.3%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.513
(+17.85% Upside)

Earnings

Latest Release
Aug 26, 2025
EPS / Forecast
0.12 / 34.20
Revenue / Forecast
28.28M / 46.00M
EPS Revisions
Last 90 days

NEU Income Statement

People Also Watch

41.920
RMD
-0.80%
299.52
PME
+0.43%
13.600
TLX
-1.45%
299.88
COH
+0.45%

FAQ

What Stock Exchange Does Neuren Pharma Trade On?

Neuren Pharma is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Neuren Pharma?

The stock symbol for Neuren Pharma is "NEU."

What Is the Neuren Pharma Market Cap?

As of today, Neuren Pharma market cap is 2.63B.

What Is Neuren Pharma's Earnings Per Share (TTM)?

The Neuren Pharma EPS (TTM) is 1.17.

When Is the Next Neuren Pharma Earnings Date?

Neuren Pharma will release its next earnings report on 02 Dec 2025.

From a Technical Analysis Perspective, Is NEU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neuren Pharma Stock Split?

Neuren Pharma has split 3 times.

How Many Employees Does Neuren Pharma Have?

Neuren Pharma has 8 employees.

What is the current trading status of Neuren Pharma (NEU)?

As of 08 Sept 2025, Neuren Pharma (NEU) is trading at a price of 20.800, with a previous close of 20.80. The stock has fluctuated within a day range of 20.140 to 20.825, while its 52-week range spans from 8.610 to 20.825.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.